Abstract Cutaneous zygomycosis remains underdiagnosed despite being frequently encountered. Delay in the diagnosis contributes to delay in treatment, and a resultant high morbidity and mortality. A retrospective analysis of the reported cases of cutaneous zygomycosis from India was made using various search engines and cross-referencing from available manuscripts. A total of 42 publications from India on the topic were identified, since the first reported case of primary cutaneous zygomycosis by Veliath et al. (1976) . There are 130 described cases of cutaneous zygomycosis with an overall mortality of 35 %. The commonest zygomycete identified was Apophysomyces elegans, and the commonest predisposing factor was breach of the skin. Surprisingly, diabetes was reported only in 36 cases (27.69 %). It is important to be aware of this unusual but fatal infection in order to manage it properly and have a good outcome.
Introduction
Zygomycosis is an infrequently encountered fungal infection caused by fungi of the phylum Zygomycota. This phylum has two main classes-Trichomycetes (which does not contain any human pathogens) and Zygomycetes, which contains the orders Mucorales and Entomophthorales, both of which can cause infection in humans.
The order Mucorales contains genera such as Mucor, Rhizopus, Rhizomucor, Absidia, Apophysomyces, Cunninghamella, Saksenaea, Syncephalastrium, and Cokeromyces, whereas Entomophthorales contains the genera Basidiobolus and Conidiobolus. Mucorales usually causes human infections in six main clinical forms-rhinocerebral, pulmonary, cutaneous, gastrointestinal, disseminated, and miscellaneous-whereas Entomophthorales is less common in causing human infection as compared to Mucorales. The term "zygomycosis" (or phycomycosis) encompasses infections by both of these orders (Mucorales and Entomophthorales). These ubiquitous fungi are present in soil and vegetation, with a worldwide distribution (with the exception of Cokeromyces which is exclusively seen in North America), but they are unable to cause infections under normal conditions [1] [2] [3] Rhinocerebral infection is the commonest form of zygomycosis in humans, followed by pulmonary infection. Cutaneous involvement is less common than these, and mainly occurs in two forms-a "benign" well-localized subcutaneous form, which usually occurs due to infection by the Entomophthorales, and a more fulminant cutaneous infection with necrotizing fasciitis, systemic sepsis, and a fatal outcome if the diagnosis and consequently the appropriate treatment is delayed [1] [2] [3] .
This study reviews the existing Indian literature on the fulminant cutaneous variety of zygomycosis.
Materials and Methods
At the outset, the aim of the study was established to identify all cases of primary cutaneous mucormycosis from India, as opposed to the more benign and localized form of subcutaneous disease that usually presents as nodular masses in the subcutaneous tissues. Primary cutaneous disease was defined as cutaneous disease in the absence of demonstrable disease elsewhere in the body. The distinction from the subcutaneous disease was made on the basis of skin involvement (ulceration, sinuses, fistulae, necrotizing fasciitis) with or without systemic sepsis, since these are the cases that are associated with a high mortality if they remain undiagnosed.
Having defined the disease parameters, a search was made of available English language literature on the topic of cutaneous zygomycosis in humans through Pubmed (and Google) using various combinations of keywords such as "cutaneous," "zygomycosis," "mucormycosis," "necrotizing fasciitis," and "India". The search pattern was further refined by using "India" along with the individual genera such as Mucor, Rhizopus, Rhizomucor, Absidia, Apophysomyces, Cunninghamella, Saksenaea, Syncephalastrum, and Cokeromyces and searching for cutaneous involvement of each.
The full text of all relevant obtained articles was analyzed for their relevance to the topic and to our country, and the bibliography of each was scanned to pick up any other relevant papers on the topic.
Results
The first reported case of primary cutaneous zygomycosis from India was by Veliath et al. in 1976 [4] , in a patient with chronic pyelonephritis and uremia, who eventually succumbed to massive pulmonary infarction as a result of dissemination of the disease from its primary site-an ulcer on the right calf (diagnosis was made postmortem). Following this, another 41 publications dealing with the topic of primary cutaneous mucormycosis in India are documented in available English language literature from 1976 till date (August 2011). Of these, 34 publications are case reports documenting 39 cases of necrotizing fasciitis due to zygomycetes and are tabulated as Table 1 . The other 8 publications are institutional series documenting the occurrence of 96 cases of cutaneous zygomycosis among the overall spectrum of zygomycotic infections and are tabulated as Table 2 [38] [39] [40] [41] [42] [43] [44] [45] . Another series by Mohapatra [46] did not clearly mention the number of cases of cutaneous infection, and is therefore not included in the final analysis. Thus, a total of 135 cases of cutaneous zygomycosis have been documented from India till date. Although such infections have been reported from all over India, the majority of cases have been reported from a single institution, the Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh.
However, there seems to be some overlapping of the data, since, after reporting a few cases of cutaneous infection, some institutions have later documented their experience with the overall spectrum of zygomycosis or zygomycotic necrotizing fasciitis, thus giving a slightly higher figure for the total number of cases reported from India in this review than is actual. These include the reports of three cases by Chakrabarti et al. in 1997 [10] , which were later included in their review of zygomycosis over a 10-year period [38] , one by Thami et al. [12] , which was later included in the series by Chander et al. [43] , and the one by Saraiya [19] , which was later reanalyzed in 2011 [45] . These cases were deducted from the total of 135 reported cases (as above) to yield 130 reported cases of zygomycotic cutaneous infection from India. Similarly, the series by Jain [41] on zygomycotic necrotizing fasciitis is bound to have included some previous cases from the same institution, but this could not be ascertained clearly. Therefore, this series was included in the overall total cases.
Overall, 128 risk factors for the development of zygomatic necrotizing fasciitis were documented. The commonest factor was breach of the skin barrier, by surgery, trauma, burns, injections, etc., that was seen in 77 cases. Next common factor was diabetes mellitus (36 cases); surprisingly, HIV infection was documented in only 1 case (Table 3) .
Species identification was available in only 65 reported cases ( Table 4 ). The commonest zygomycete identified was Apophysomyces elegans (35 cases), followed by Rhizopus (11 cases), and Saksenaea (7 cases). A new species of Apophysomyces (A. variabilis) was documented in a case reported from Chandigarh in 2011 [35] , and on review, four previously documented infections as Apophysomyces elegans from the same institution were found to be due to this new species, thus bringing the number of cases due to Apophysomyces elegans down to 31.
Of the outcomes available (80 cases), there were 25 deaths, and three patients left against medical advice, possibly not having survived the infections, giving a mortality rate of 35 %.
Discussion
Being a retrospective analysis, this review has all the limitations of such a study, as one can only analyze what already exists in literature. The main limitation that immediately comes to mind is there is a lack of clarity in clearly identifying the two different varieties of cutaneous zygomycosis -the fulminant cutaneous infections and the more "benign" subcutaneous variety. This is true especially in the major series that have dealt with this topic, and this distinction has not been made clearly, even though both patterns of disease have a markedly different clinical presentation, geographical incidence, and fungal profile. As mentioned previously, the disease can present with cutaneous involvement in the form (12) R oryzae (1) Survival (14) HIV (1) R microsporus (1) Chronic alcoholism (1) Jain (2006) a New sub-species of Apophysomyces (Apophysomyces variabilis) identified in 2010. 04 of previously reported cases as Apophysomyces elegans were later identified to be Apophysomyces variabilis [35] it has a much better outcome and prognosis. Even in a major review of the spectrum of zygomycosis in India in 2007 [47] , the authors did not make any distinction between these two forms, and they were clubbed together as the cutaneous variety. Therefore, again it is stressed that we should clearly document whether the disease is cutaneous or subcutaneous, especially in major reviews, where the two may be clubbed together.
Having noted this, the number of 130 cases of cutaneous zygomycosis since the first report in 1976 is probably much lower than the actual incidence of the disease in India. This may be due to many reasons, main among them a lack of awareness of this disease among our various health care providers-the mortality in these patients with cutaneous zygomycosis who remain undiagnosed and therefore improperly treated contribute to the low reported incidence (since the patient may die prior to the correct diagnosis having been made). It is therefore important to spread awareness of this disease so that the diagnosis can be made early, timely treatment can be started, and hopefully, a good outcome assured to the patient.
As a rule, cutaneous infection by these fungi does not occur in healthy individuals, or across an intact skin barrier. The major risk factors documented for the development of zygomycosis can be broadly classified as immunosuppressive states (hematological or other malignancies, neutropenia, steroids, anticancer therapy, malnutrition, posttransplant states and immunosuppression), breach of the skin barrier (surgery, trauma, burns, injections, IV lines, insect bites, and even from contaminated dressings), desferrioxamine therapy, and diabetes [1-3, 47, 48] . For cutaneous infection, a breach in the skin barrier is probably the most important risk factor, and has been reported in 77 of these 130 cases from India (59.23 %), slightly lower to that reported in literature. In a major review, Roden et al. calculated penetrating trauma to be present in 72.7 % of cases with cutaneous involvement [48] . Of the 53 (40.76 %) underlying diseases reported in these 130 patients, diabetes was an important underlying condition/risk factor, seen in 36 patients (27.69 %)-again, very similar to what has been reported previously in literature [48] . However, it is also important to realize that nearly 73 % of these patients did not have diabetes, thus making the disease more common in nondiabetic patients. Equally important to note is that in nearly 60 % of the patients, there was no underlying disease condition at presentation. It is well known that cutaneous involvement is the form of zygomycosis that is least likely to be associated with any underlying illness, and our literature seems to support this [1, 3] .
The presentation of cutaneous zygomycosis is wide and varied, and it can present as necrotizing infections (cellulitis or ulcerations), sinuses, blisters, or fungating masses with an aggressive local disease progression, along with severe systemic sepsis. The infection should be classified as localized (infection remains confined to the skin and subcutaneous tissue), deep (spread into the deeper tissues such as muscles, tendons, or bones), or disseminated (involvement of another noncontiguous site). It is rare for cutaneous zygomycosis to develop secondarily from infection at other sites, and it remains mainly a primary disease, where the portal of entry is through the skin [3] . Documenting the patients clearly with the level of infection will help in further prognostication of outcomes in the future.
The diagnosis of zygomycotic cutaneous infection is made by showing the fungus within the cells along with angioinvasion, and not merely on the basis of staining or wound cultures, since this can simply represent contamination. In suspicious cases (e.g., a patient with history of intervention, local necrotizing infection, and systemic sepsis), it is advisable to get a frozen section of the tissue specimen to help in early diagnosis and treatment planning, rather than to wait for the biopsy to come in routine (by which time it may already be too late for the patient). The cultures and other morphological features help in the species identification, which was available in 65 reported cases (Table 4) ; the commonest zygomycete identified was Apophysomyces elegans (in 31 cases), which usually causes the cutaneous variety of infection, more so in patients who are not immunocompromised [3] .
The treatment for cutaneous zygomycosis is aggressive surgical debridement along with antifungal therapy. Amphotericin B is the drug of choice since these fungi are resistant to the majority of the antifungal drugs available. Posaconazole is also effective, but itraconazole and voriconazole have shown no efficacy in these infections. The main side effect of amphotericin B is renal failure, and starting it in incremental doses (not to exceed a dose of 0.5-0.75 mg/kg/day) may help to reduce its side effects. Liposomal amphotericin B is less nephrotoxic than amphotericin B deoxycholate, but the costs of the drug may preclude usage in poor patients, contributing to the mortality (34.28 %) seen from India. Recently, Saraiya from Ahmedabad has reported better survival in patients who undergo debridement at least 10 days after starting amphotericin, based on the reported experiences in the management of orbital mucormycosis [45] . Maybe this gives time for the drug to reach desirable concentration in the blood, and also helps to tackle the fungi that may have invaded the bloodstream and be responsible for the failures after early debridement. This is an important concept that needs to be evaluated further, but the main drawback of this is that necrotizing fasciitis is usually debrided at the earliest-this protocol can only be followed once the diagnosis is made-and for that, a high index of suspicion is required on the part of the treating surgeon.
